BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 37932477)

  • 1. [The two-in-one hit model of the short-cut carcinogenesis of colorectal carcinomas in MLH1-associated Lynch syndrome].
    Ahadova A; Stenzinger A; Seppälä T; Hüneburg R; Kloor M; Bläker H
    Pathologie (Heidelb); 2023 Dec; 44(Suppl 3):188-192. PubMed ID: 37932477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Associations of Pathogenic Variants in MLH1, MSH2, and MSH6 With Risk of Colorectal Adenomas and Tumors and With Somatic Mutations in Patients With Lynch Syndrome.
    Engel C; Ahadova A; Seppälä TT; Aretz S; Bigirwamungu-Bargeman M; Bläker H; Bucksch K; Büttner R; de Vos Tot Nederveen Cappel WT; Endris V; Holinski-Feder E; Holzapfel S; Hüneburg R; Jacobs MAJM; Koornstra JJ; Langers AM; Lepistö A; Morak M; Möslein G; Peltomäki P; Pylvänäinen K; Rahner N; Renkonen-Sinisalo L; Schulmann K; Steinke-Lange V; Stenzinger A; Strassburg CP; van de Meeberg PC; van Kouwen M; van Leerdam M; Vangala DB; Vecht J; Verhulst ML; von Knebel Doeberitz M; Weitz J; Zachariae S; Loeffler M; Mecklin JP; Kloor M; Vasen HF; ;
    Gastroenterology; 2020 Apr; 158(5):1326-1333. PubMed ID: 31926173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patients with colorectal cancer associated with Lynch syndrome and MLH1 promoter hypermethylation have similar prognoses.
    Haraldsdottir S; Hampel H; Wu C; Weng DY; Shields PG; Frankel WL; Pan X; de la Chapelle A; Goldberg RM; Bekaii-Saab T
    Genet Med; 2016 Sep; 18(9):863-8. PubMed ID: 26866578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MLH1-deficient Colorectal Carcinoma With Wild-type BRAF and MLH1 Promoter Hypermethylation Harbor KRAS Mutations and Arise From Conventional Adenomas.
    Farchoukh L; Kuan SF; Dudley B; Brand R; Nikiforova M; Pai RK
    Am J Surg Pathol; 2016 Oct; 40(10):1390-9. PubMed ID: 27438990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Routine Molecular Analysis for Lynch Syndrome Among Adenomas or Colorectal Cancer Within a National Screening Program.
    Goverde A; Wagner A; Bruno MJ; Hofstra RMW; Doukas M; van der Weiden MM; Dubbink HJ; Dinjens WNM; Spaander MCW
    Gastroenterology; 2018 Nov; 155(5):1410-1415. PubMed ID: 30063919
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of somatic mutl homolog 1 promoter hypermethylation in Lynch syndrome colorectal cancer.
    Moreira L; Muñoz J; Cuatrecasas M; Quintanilla I; Leoz ML; Carballal S; Ocaña T; López-Cerón M; Pellise M; Castellví-Bel S; Jover R; Andreu M; Carracedo A; Xicola RM; Llor X; Boland CR; Goel A; Castells A; Balaguer F;
    Cancer; 2015 May; 121(9):1395-404. PubMed ID: 25557234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lynch syndrome-associated colorectal carcinoma: frequent involvement of the left colon and rectum and late-onset presentation supports a universal screening approach.
    Hartman DJ; Brand RE; Hu H; Bahary N; Dudley B; Chiosea SI; Nikiforova MN; Pai RK
    Hum Pathol; 2013 Nov; 44(11):2518-28. PubMed ID: 24034859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lessons learnt from implementation of a Lynch syndrome screening program for patients with gynaecological malignancy.
    Najdawi F; Crook A; Maidens J; McEvoy C; Fellowes A; Pickett J; Ho M; Nevell D; McIlroy K; Sheen A; Sioson L; Ahadi M; Turchini J; Clarkson A; Hogg R; Valmadre S; Gard G; Dooley SJ; Scott RJ; Fox SB; Field M; Gill AJ
    Pathology; 2017 Aug; 49(5):457-464. PubMed ID: 28669579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumour MLH1 promoter region methylation testing is an effective prescreen for Lynch Syndrome (HNPCC).
    Newton K; Jorgensen NM; Wallace AJ; Buchanan DD; Lalloo F; McMahon RF; Hill J; Evans DG
    J Med Genet; 2014 Dec; 51(12):789-96. PubMed ID: 25280751
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Carnevali IW; Cini G; Libera L; Sahnane N; Facchi S; Viel A; Sessa F; Tibiletti MG
    Genes (Basel); 2023 Nov; 14(11):. PubMed ID: 38003003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The First Molecular Screening of MLH1 and MSH2 Genes in Moroccan Colorectal Cancer Patients Shows a Relatively High Mutational Prevalence.
    Moufid FZ; Bouguenouch L; El Bouchikhi I; Chbani L; Iraqui Houssaini M; Sekal M; Belhassan K; Bennani B; Ouldim K
    Genet Test Mol Biomarkers; 2018 Aug; 22(8):492-497. PubMed ID: 30044143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidemiological, clinical and molecular characterization of Lynch-like syndrome: A population-based study.
    Porkka N; Lahtinen L; Ahtiainen M; Böhm JP; Kuopio T; Eldfors S; Mecklin JP; Seppälä TT; Peltomäki P
    Int J Cancer; 2019 Jul; 145(1):87-98. PubMed ID: 30575961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Screening for germline mutations of MLH1, MSH2, MSH6 and PMS2 genes in Slovenian colorectal cancer patients: implications for a population specific detection strategy of Lynch syndrome.
    Berginc G; Bracko M; Ravnik-Glavac M; Glavac D
    Fam Cancer; 2009; 8(4):421-9. PubMed ID: 19526325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinomas, Including Lynch Syndrome-associated and MLH1 Promoter Hypermethylated Tumors.
    Sloan EA; Ring KL; Willis BC; Modesitt SC; Mills AM
    Am J Surg Pathol; 2017 Mar; 41(3):326-333. PubMed ID: 27984238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency.
    Cohen R; Buhard O; Cervera P; Hain E; Dumont S; Bardier A; Bachet JB; Gornet JM; Lopez-Trabada D; Dumont S; Kaci R; Bertheau P; Renaud F; Bibeau F; Parc Y; Vernerey D; Duval A; Svrcek M; André T
    Eur J Cancer; 2017 Nov; 86():266-274. PubMed ID: 29055842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Redundant DNA methylation in colorectal cancers of Lynch-syndrome patients.
    Alemayehu A; Sebova K; Fridrichova I
    Genes Chromosomes Cancer; 2008 Oct; 47(10):906-14. PubMed ID: 18618713
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular Background of Colorectal Tumors From Patients With Lynch Syndrome Associated With Germline Variants in PMS2.
    Ten Broeke SW; van Bavel TC; Jansen AML; Gómez-García E; Hes FJ; van Hest LP; Letteboer TGW; Olderode-Berends MJW; Ruano D; Spruijt L; Suerink M; Tops CM; van Eijk R; Morreau H; van Wezel T; Nielsen M
    Gastroenterology; 2018 Sep; 155(3):844-851. PubMed ID: 29758216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pseudomyxoma peritonei of a mature ovarian teratoma caused by mismatch repair deficiency in a patient with Lynch syndrome: a case report.
    Gohda Y; Noguchi R; Horie T; Igari T; Nakamura H; Ohta Y; Yamaguchi K; Ikenoue T; Hatakeyama S; Yusa N; Furukawa Y; Yano H
    BMC Med Genet; 2016 Dec; 17(1):94. PubMed ID: 27938333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive analysis of the
    Morak M; Ibisler A; Keller G; Jessen E; Laner A; Gonzales-Fassrainer D; Locher M; Massdorf T; Nissen AM; Benet-Pagès A; Holinski-Feder E
    J Med Genet; 2018 Apr; 55(4):240-248. PubMed ID: 29472279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A "Two-in-One Hit" Model of Shortcut Carcinogenesis in MLH1 Lynch Syndrome Carriers.
    Ahadova A; Stenzinger A; Seppälä T; Hüneburg R; Kloor M; Bläker H;
    Gastroenterology; 2023 Jul; 165(1):267-270.e4. PubMed ID: 36907525
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.